Stratification by the HAVOC risk score identified patients at highest risk for AF detection at 18 months, with incidence rates of 19.5% for low, 32.1% for intermediate, and 34.2% for high scores.
Cohort (n=391)
Does the HAVOC risk score predict atrial fibrillation detection by insertable cardiac monitors in high-risk patients without recent stroke?
The HAVOC risk score effectively identifies patients without recent stroke who are at the highest risk of developing atrial fibrillation and may benefit most from long-term monitoring with insertable cardiac monitors.
BACKGROUND: Recent studies using insertable cardiac monitors (ICMs) show a high incidence of atrial fibrillation (AF). Further identifying subsets of patients who could benefit most from ICMs is desirable. We evaluated whether the HAVOC risk score which predicts AF in patients with cryptogenic stroke also predicts AF detection by ICMs in those without recent stroke. METHODS: Participants were included from the prospective, industry-sponsored REVEAL AF study assessing AF incidence in patients with CHADS2 scores ≥3 or =2 with 1 or more additional AF risk factors, who had ICM data and were not receiving anti-arrhythmic drugs. Ischemic stroke occurring less than 1 year prior to enrollment or documented AF were exclusion criteria. AF was defined as an adjudicated ICM-detected episode ≥6 min in duration. HAVOC scores were calculated by assigning 4 points for congestive heart failure, 2 points for each of hypertension, age ≥75 years, valvular disease, and coronary artery disease, and 1 point for each of peripheral vascular disease and obesity (body mass index >30). Scores classified risk as low (0-4), intermediate (5-9), or high (10-14); corresponding AF detection rates were compared using the log-rank test. AF incidence rates in patients with and without a history of remote stroke at baseline were also compared. RESULTS: Among 391 participants, the mean age was 71.5 ± 9.8 years and 186 (47.6%) were women. In total, 130 (33.2%) developed AF over 18 months. Stratification by HAVOC risk score was: 95 (24%) low, 241 (62%) intermediate, and 55 (14%) high. At 18 months, AF incidence in patients with low HAVOC scores (19.5%) was lower than in those with intermediate (32.1%) or high (34.2%) scores. AF incidence was similar among those with (n = 78) versus without (n = 313) remote stroke (27.3% vs. 29.8%; median time from stroke to ICM insertion was 4.2 2.2-8.2 years). CONCLUSIONS: The HAVOC risk score identified a subset of individuals at greatest risk of developing AF, while AF incidence rates were similar among those with and without remote stroke. The use of the HAVOC score could help identify those at greatest likelihood of manifesting AF during long-term monitoring.
Elkind et al. (Fri,) conducted a cohort in High risk for atrial fibrillation (n=391). HAVOC risk score was evaluated on Adjudicated ICM-detected AF episode ≥6 min in duration. Stratification by the HAVOC risk score identified patients at highest risk for AF detection at 18 months, with incidence rates of 19.5% for low, 32.1% for intermediate, and 34.2% for high scores.